Currently out of the existing stock ratings of Michael Okunewitch, 1 are a HOLD (8.33%), 11 are a BUY (91.67%).

Michael Okunewitch

Work Performance Price Targets & Ratings Chart

Analyst Michael Okunewitch, currently employed at MAXIM GROUP, carries an average stock price target met ratio of 21.43% that have a potential upside of 31.39% achieved within 12 days.

Michael Okunewitch’s has documented 23 price targets and ratings displayed on 7 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on HCWB, HCW Biologics at 28-May-2025.

Wall Street Analyst Michael Okunewitch

Analyst best performing recommendations are on ANEB (ANEBULO PHARMACEUTICALS).
The best stock recommendation documented was for ANEB (ANEBULO PHARMACEUTICALS) at 5/15/2025. The price target of $3 was fulfilled within 69 days with a profit of $1.99 (197.03%) receiving and performance score of 28.56.
ATAI ATAI Life Sciences BV CTXR Citius Pharmaceuticals KPRX Kiora Pharmaceuticals BRTX BioRestorative Therapies ANEB Anebulo Pharmaceuticals CMMB Chemomab Therapeutics Ltd DRC HCWB HCW Biologics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$15

$9.9 (194.12%)

$10

2 months 14 days ago
(29-Jul-2025)

0/5 (0%)

$11.53 (332.28%)

Buy

$11

$5.9 (115.69%)

$12

2 months 16 days ago
(27-Jul-2025)

0/4 (0%)

$7.67 (230.33%)

Buy

1 years 3 months 23 days ago
(20-Jun-2024)

0/1 (0%)

$26.23 (139.74%)

Buy

$9

$3.9 (76.47%)

2 years 5 months 2 days ago
(11-May-2023)

0/3 (0%)

$7.1 (373.68%)

Buy

2 years 6 months 16 days ago
(27-Mar-2023)

0/1 (0%)

$17.08 (114.48%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Michael Okunewitch is most bullish on?

Potential upside of $30.46 has been obtained for HCWB (HCW BIOLOGICS)

Which stock is Michael Okunewitch is most reserved on?

Potential downside of $0.68 has been obtained for ANEB (ANEBULO PHARMACEUTICALS)

What Year was the first public recommendation made by Michael Okunewitch?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?